

I hereby certify that this correspondence is being filed via EFS-Web with the United States Patent and Trademark Office on the date shown below:

PATENT
Attorney Docket No.: 021044-001210US
Client Reference No.: P.0071.01.US

On February 27, 2007

TOWNSEND and TOWNSEND and CREW LLP

By: Raen Karlin

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Yasumichi Hitoshi et al.

Application No.: 10/026,021

Filed: December 21, 2001

For: SAK: MODULATION OF
CELLULAR PROLIFERATION FOR
TREATMENT OF CANCER

Confirmation No.: 6123

Examiner: Misook Yu

Art Unit: 1642

SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT UNDER
37 CFR §1.97 and §1.98

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The references cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. Copies of the references [in compliance with the requirements of 37 CFR §1.98(a)(2)] are enclosed.

Also enclosed is a copy of the Search report corresponding to the European application (EP Application No. 02750377.0).


It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR §1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

This Information Disclosure Statement is being filed concurrently with a Request for Continued Examination. A Notice of Allowance was mailed on November 30, 2006. This Information Disclosure Statement and the Request for Continued Examination are being filed on or before the due date of the Issue Fee, which is February 28, 2007.

Applicant believes that no fee is required for submission of this statement. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,



Annette S. Parent
Reg. No. 42,058

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
Tel: 925-472-5000
Fax: 925-472-8895
ASP:kkk

Substitute for form 1449A&B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known		
				Application Number	10/026,021	
				Filing Date	December 21, 2001	
				First Named Inventor	Hitooshi, Yasumichi	
				Art Unit	1642	
Examiner Name	Misook Yu					
Attorney Docket Number	021044-001210US					
Sheet	1	of	1			

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	1	FODE, Carol, et al., "Constitutive Expression of Murine Sak-a Suppresses Cell Growth and Induces Multinucleation," Molecular and Cellular Biology, 1996, Vol. 16, No. 9, pp 4665-4672.	<input type="checkbox"/>
	2	HIRAO, Atsushi, et al. "DNA Damage-Induced Activation of p53 by the Checkpoint Kinase Chk2," Science, 2000, Vol. 287, pp 1824-1827.	<input type="checkbox"/>
	3	KARN, Thomas, et al., "Human SAK related to the PLK/polo family of cell cycle kinases shows high mRNA expression in testis," Oncology Reports, 1997, Vol. 4, pp 505-510.	<input type="checkbox"/>
	4	LUKAS, Claudia, et al., "DNA Damage-activated Kinase Chk2 Is Independent of Proliferation or Differentiation Yet Correlates with Tissue Biology," Cancer Research, 2001, Vol. 61, pp 4990-4993.	<input type="checkbox"/>
	5	MACMILLAN, Jennifer C., et al., "Comparative Expression of the Mitotic Regulators SAK and PLK in Colorectal Cancer," Annals of Surgical Oncology, Vol. 8, No. 9, pp 729-740.	<input type="checkbox"/>

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.